Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide – might not be able to ...

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, ...

MALVERN, Pa. and KENILWORTH, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Centocor, Inc. and Schering-Plough Corporation today announced that the European Commission has ...

Dec. 22, 2004 — The U.S. Food and Drug Administration (FDA) and Centocor have warned healthcare professionals via letter regarding risks of hepatotoxicity and pneumonia associated with the use of ...

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid ...

INCHEON, South Korea--(BUSINESS WIRE)--A new post-hoc analysis of a pivotal phase III randomised controlled clinical trial shows that the subcutaneous (SC) formulation of infliximab, Remsima ® (CT-P13 ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...

Please provide your email address to receive an email when new articles are posted on . The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to ...